News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Stratatech Closes $3-Million Funding Round to Advance Clinical Trial


5/4/2010 11:39:33 AM

MADISON, Wis.--(BUSINESS WIRE)--Stratatech Corp., a regenerative medicine company focused on the commercialization of cell-based, tissue-engineered skin substitute products, today announced that it has closed a $3.0-million round of funding comprised of convertible notes. The funding was secured from current investors in the company. The proceeds will be used to advance the clinical trial of the company’s StrataGraft® living human skin substitute tissue. The company expects to begin Phase IIb of the trial during the second half of 2010.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES